Myocyte enhancer factor 2 activates promoter sequences of the human AbetaH-J-J locus, encoding aspartyl-beta-hydroxylase, junctin, and junctate by Feriotto, Giordana et al.
MOLECULAR AND CELLULAR BIOLOGY, Apr. 2005, p. 3261–3275 Vol. 25, No. 8
0270-7306/05/$08.000 doi:10.1128/MCB.25.8.3261–3275.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Myocyte Enhancer Factor 2 Activates Promoter Sequences of the
Human AH-J-J Locus, Encoding Aspartyl--Hydroxylase,
Junctin, and Junctate
Giordana Feriotto,1 Alessia Finotti,2 Pompeo Volpe,3 Susan Treves,4 Stefano Ferrari,5
Cecilia Angelelli,5 Francesco Zorzato,6 and Roberto Gambari2*
Biotechnology Center,1 Department of Biochemistry and Molecular Biology, Section of Molecular Biology,2 and
Department of Experimental and Diagnostic Medicine, Section of General Pathology,6 University of Ferrara,
Ferrara, Department of Biomedical Experimental Sciences, University of Padova, Padova,3 and
Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena,5
Italy, and Departments of Anaesthesia and Research,
Kantonsspital, Basel, Switzerland4
Received 23 August 2004/Returned for modification 27 September 2004/Accepted 30 December 2004
Alternative splicing of the locus AH-J-J generates three functionally distinct proteins: an enzyme, AH
(aspartyl--hydroxylase), a structural protein of the sarcoplasmic reticulum membrane (junctin), and an
integral membrane calcium binding protein (junctate). Junctin and junctate are two important proteins
involved in calcium regulation in eukaryotic cells. To understand the regulation of these two proteins, we
identified and functionally characterized one of the two promoter sequences of the AH-J-J locus. We
demonstrate that the P2 promoter of the AH-J-J locus contains (i) a minimal sequence localized within a
region 159 bp from the transcription initiation site, which is sufficient to activate transcription of both
mRNAs; (ii) sequences which bind known transcriptional factors such as those belonging to the myocyte
enhancer factor 2 (MEF-2), MEF-3, and NF-B protein families; and (iii) sequences bound by unknown
proteins. The functional characterization of the minimal promoter in C2C12 cells and in the rat soleus muscle
in vivo model indicates the existence of cis elements having positive and negative effects on transcription. In
addition, our data demonstrate that in striated muscle cells the calcium-dependent transcription factor MEF-2
is crucial for the transcription activity directed by the P2 promoter. The transcription directed by the AH-J-J
P2 promoter is induced by high expression of MEF-2, further stimulated by calcineurin and Ca2/calmodulin-
dependent protein kinase I, and inhibited by histone deacetylase 4.
Skeletal muscle contraction involves the transduction of an
electrical signal, generated at the neuromuscular junction, into
a transient increase of [Ca2]i within the skeletal muscle fiber
via a mechanism which is referred to as excitation-contraction
(EC) coupling (35). The sarcoplasmic reticulum (SR) is the
intracellular membrane compartment of striated muscle that
controls the intracellular calcium concentration and therefore
plays an important role in EC coupling (35). The anatomical
site of EC coupling is the triad, an intracellular synapse formed
by the association of two membrane compartments, the trans-
verse tubules, which are an invagination of the plasmalemma,
and the sarcoplasmic reticulum terminal cisternae. The portion
of terminal cisternae facing the transverse tubules is called the
junctional face membrane. Two major protein constituents of
the triad membranes have been identified and shown to play a
crucial role in EC coupling (35): the dihydropyridine receptors
(DHPRs), localized in T-tubule membrane, and the ryanodine
receptors (RyRs), localized in the terminal cisternae of the
sarcoplasmic reticulum junctional face membrane. In skeletal
muscle the dihydropyridine receptors respond to transverse
tubule depolarization by sensing the voltage variation and in-
duce calcium release from the skeletal muscle sarcoplasmic
reticulum via direct activation of the RyR. The SR and T
tubule membranes are also endowed with a variety of known
proteins involved in calcium storage (calsequestrin) (18), signal
transduction between the transverse tubule and SR (triadin,
junctin, protein kinases, and their regulators) (21, 69), and
calcium homeostasis (Ca pump and Na/Ca exchanger) (39).
The triad membranes undergo profound structural changes
during adaptive responses to disuse and denervation muscle
atrophy, suggesting that this membrane compartment could be
involved in the mechanism responsible for muscle adaptation
and development (44, 54, 58). Muscle disuse seems to induce a
complex response entailing a set of transcription factors which
are involved in an earlier developmental stage and include high
levels of Id and some specific myogenic factors and immediate-
early gene products, as well as either down-regulation, e.g.,
myosin light and heavy chains, or up-regulation, e.g., dihydro-
pyridine receptor, of several muscle-specific genes (12, 22, 1,
44). Moreover, muscle adaptation may entail two distinct path-
ways, for immediate-early responses and for long-term re-
sponses. The genetic hierarchy controlling skeletal muscle
myogenesis and differentiation as well as adaptive responses,
such as disuse atrophy, compensatory hypertrophy, or dener-
vated degradation, is far from being completely understood at
the gene and protein levels (55). Thus, comprehension of the
regulation of the expression of the genes involved in EC cou-
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pling is crucial not only to understand the mechanism(s) lead-
ing to the mechanical properties of muscle fibers under normal
and adapting conditions but also to unravel the signaling path-
way involved in this adaptation.
The specific regulatory DNA sequences and the relative
transcription factors of most of the genes involved in EC cou-
pling, such as Ca2-ATPase, calsequestrin, ryanodine receptor,
triadin, junctin, and dihydropyridyne receptor, are not known.
However, little is known about the mechanisms underlying
transcriptional control in normal muscles and in muscles dur-
ing adaptive processes.
We have recently cloned, sequenced, and characterized the
AH-J-J locus, a genomic sequence which generates three
functionally distinct proteins which are differentially expressed
in various tissues. In addition to the enzyme aspartyl--hydrox-
ylase (AH), this locus encodes junctin a structural protein of
SR and the membrane-bound calcium binding protein junctate
(60, 61). Junctate is a novel integral calcium binding protein of
sarco(endo)plasmic reticulum membrane, which is likely in-
volved in calcium signaling in both excitable and nonexcitable
cells (25, 61). Since these proteins are generated by alternative
splicing of the primary transcripts of the AH-J-J locus (60),
the transcriptional regulation of the AH-J-J locus is expected
to be quite complex.
To date, little has been known about the promoter se-
quences regulating the expression of the AH-J-J locus. In
particular, no data are available on the possible promoter
activity of regions located upstream of the junctin sequences.
To understand how expression of the three main transcripts of
the AH-J-J locus is regulated, we have cloned, sequenced,
and analyzed one of the two putative promoter sequences
regulating the transcription of junctin, junctate, and aspartyl-
-hydroxylase.
MATERIALS AND METHODS
Cell cultures. C2C12 mouse muscle myoblast, H9c2 rat heart myoblast, RD
human embryonic rhabdomyosarcoma, HepG2 human hepatoblastoma, and
HeLa human cervix epithelial carcinoma cell lines were cultured as described
previously (27, 28, 49, 57, 67). C2C12-GM cells were cultured in medium sup-
plemented with 10% fetal calf serum (growth medium [GM]), differentiated
C2C12-DM cells were obtained by culturing cells in medium supplemented with
2% horse serum plus 10 g of insulin (Sigma)/ml (differentiation medium [DM])
for 72 h before nuclear extraction, and total RNA purification or chromatin
immunoprecipitation (ChIP) assays were performed (52).
RT-PCR. Total RNA from human adult normal tissue was purchased from BD
Biosciences Clontech (Palo Alto, Calif.). Total RNA was harvested from RD,
C2C12-GM, or C2C12-DM cell lines by using TRIzol reagent (Invitrogen, Carls-
bad, Calif.). cDNA was synthesized from 2 g of total RNA by the use of
ImProm-II (Promega, Madison, Wis.). PCR was performed using a GeneAmp
PCR 9600 system (Perkin Elmer) 1/20 of reverse transcription reaction mixture
(cDNA), the e2F forward primer (5-ACC TGC CAG CAG TAC TTT TG-3),
and the e3R reverse primer (5-TTC CTG AGA GTC CGC CTT TC-3) or the
e2F1 forward primer (5-TTC ATG GAT TGA AGA AAT CAA AAT G-3) and
the e5R reverse primer (5-AAT AAA ACT TTG GCA TCA TCC ACA TCA
AAA TCT CC-3) (designed to amplify products of 147 and 255 bp, respectively,
and spanning one or more introns to rule out amplification from genomic DNA)
(60), 2 U of Taq polymerase, and 33 M deoxynucleoside triphosphates; the
PCR conditions were as follows: 30 or 35 cycles of amplification, respectively,
with 15 s of denaturation at 95°C, 30 s of annealing at 62°C, and 20 s of
elongation at 72°C. Starting total RNA were normalized by performing reverse
transcription-PCR (RT-PCR) of the beta-2 microglobulin housekeeping gene
(data not shown).
5 RACE. Total RNA (1 g), purified from human adult skeletal muscle or
from RD cells, was subjected to 5 rapid amplification of cDNA ends (RACE) by
the use of a 5 RACE system (Life Technologies, Gaithersburg, Md.). cDNA was
FIG. 1. Structure of the 5 end of the human locus for aspartyl--hydroxylase, junctin, and junctate. Arabic numbers over black boxes indicate
exons. Intervening sequences are indicated in roman numerals. The two putative promoters P1 and P2 are indicated. A schematic representation
of aspartyl--hydroxylase, junctin, and junctate exon splicing (11, 60) is shown at the bottom of the panel. The cytoplasmic, transmembrane (TM),
positively charged, calcium binding, and catalytic domains are indicated. The locations of AUG, stop codons, and poly(A) signals are shown. The
BglII (B) plasmid subclone of BAC 1 (60) covering the second exon of the locus is also shown.
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synthesized using the primer e5R, complementary to an exon 5 sequence of the
AH-J-J locus (Fig. 1 and 2) (60), and a poly(G) tail was added by terminal
transferase. PCR was performed using this cDNA as the template, 5 RACE
Ambriged anchor primer, and the primer e3R complementary to an exon 3
sequence (60). A dilution of the original PCR was reamplified using 5 RACE
Ambriged universal amplification primer and the nested primer e2R (5-ATC
TTC AGC CAT TTT GAT TTC TTC AAT CC-3) complementary to an exon
2 sequence. PCR products were purified with Microcon-30 (Millipore, Bedford,
Mass.) and subjected to direct sequencing with an ABI PRISM BigDye termi-
nator cycle sequencing ready reaction kit and an ABI PRISM 377 DNA se-
quencer (PE Applied Biosystems, Foster City, Calif.). Moreover, PCR products
were cloned with a pGEM-T Vector System (Promega) and recombinant plas-
mids were sequenced. The transcription initiation site observed by 5 RACE was
numbered 1, and all the other sites are numbered relative to it.
Cloning of the AH-J-J P2 promoter and reporter plasmid construction. The
BglII fragment of the human chromosome 8 BAC 1 clone (60) was cloned into
the pUC18 vector and sequenced. The insert encompasses exon 2 of the AH-J-J
locus (Fig. 1) and contains the putative P2 promoter. The sequence correspond-
ing to 686 to 115, relative to the transcription initiation site, was amplified by
using a GeneAmp High Fidelity PCR system (Applied Biosystems) and the
5-ATG TGG TTG TGT AAT CTT TTC CTA GTT C-3 forward and 5-CTT
CAA TCC ATG AAT AAT AAA TGC TAA AGT-3 reverse primers, contain-
ing a BglII and an NcoI restriction site, respectively. The PCR product was
cloned into the BglII/NcoI restriction sites of pGL3-basic firefly luciferase re-
porter plasmid (Promega). Nine serial deletion constructs were generated from
this recombinant plasmid by the use of an Exo III/S1 deletion kit (Fermentas,
Vilnius, Lithuania). The sequence of all the constructs was confirmed by DNA
sequencing.
Transient transfection and dual luciferase assay. Cells were seeded at 40 to
60% confluence in 16-mm-diameter wells. Transfection was performed after 24 h
by the use of 2 g of Lipofectamine 2000 (Life Technologies) and 60 ng of
pRL-TK vector (Promega), which contains the Renilla luciferase gene as a
transfection efficiency control and 1 g of firefly luciferase reporter plasmid per
well (or 0.5 g each of three constructs in the cotransfections with expression
vectors or void vectors). C2C12-DM were seeded at 90% confluence and trans-
fected in medium supplemented with 2% horse serum–10 g of insulin/ml.
Lysates were prepared 24 to 48 h after transfection by adding 100 l of passive
lysis buffer (Dual Luciferase reporter assay system; Promega), and luciferase
activity was determined with an analytical luminometer (model TD-20/20;
Turner Designs, Sunnyvale, Calif.). Relative luciferase units (RLU) were calcu-
lated by determining the ratio of the intensity of the light produced by the firefly
luciferase reporter plasmid to that produced by the Renilla luciferase pRL-TK
plasmid.
Triplicate luciferase assays of all the samples were performed. Severalfold
induction results were determined by calculating the ratio of the firefly luciferase
reporter plasmid RLU to that produced by the pGL3-basic vector with basal
promoter activity. pcDNAI/A myocyte enhancer factor 2 (MEF-2A), kindly
provided by E.N. Olson, has been described by Black et al. (4) and was made by
cloning the coding region of human MEF-2A into the polylinker of the pCDNAI/
Amp plasmid (Invitrogen, Inc.) (68). A plasmid encoding Myc-tagged histone
deacetylase 4 (HDAC4), pHDAC4-Myc, was a kind gift of T. Kouzarides (Uni-
versity of Cambridge, Cambridge, United Kingdom) (43). pHDAC4-Myc Del
FIG. 2. (A) In the upper part of the panel, the three transcripts starting from the P2 promoter, the PCR primers, and the 147-bp and the 255-bp
() PCR products are represented; black boxes indicate exons common to the three transcripts; grey boxes indicate exons common only to
aspartyl--hydroxylase and junctate. Oligo(dT) RT-PCR was performed with total RNA isolated from human adult normal tissues or cell lines with
the e2F/e3R (lanes a to g) or the e2F1/e5R (lanes h and i) primers and analyzed with agarose gel electrophoresis (lower part of panel). Lanes:
a, kidney; b, brain; c, adrenal gland; d, liver; e, heart; f, skeletal muscle; g, RD cell line; h, C2C12-GM cells (C2C12 cells cultured in growth medium
in the presence of 10% fetal calf serum); i, C2C12-DM cells (C2C12 cells cultured in differentiation medium in the presence of 2% horse serum
and 10 g of insulin/ml); M, pUC Mix Marker 8 (Fermentas). (B) Analysis of 5 RACE products of AH-J-J exon 2 starting transcripts. cDNAs
were synthesized from RD cells (lane m) or human adult skeletal muscle (lane n) total RNA by using the e5R primer. After addition of a
poly(G) tail, PCR was performed with the gene-specific e3R primer. One-fifth of the nested PCRs, after a procedure performed with a
gene-specific e2R primer, was analyzed by gel electrophoresis. Lanes j to l, control reactions from RD cell RNA performed in the absence of
reverse transcriptase, terminal deoxynucleotidyl transferase, and both, respectively. (C) Nucleotide sequence of RACE products, obtained by direct
sequencing or cloning. The P2 transcription initiation site (1), the primers used for the last PCR, and the translation start site (ATG) are
indicated.
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119-208 ( MEF-2 binding domain [bind. d.]), from which the MEF-2 binding
site had been removed, was produced with a QuikChange site-directed mutagen-
esis kit (Stratagene, La Jolla, Calif.). For the production of FLAG-HDAC4 1-233
( catalytic d.), a fragment encoding amino acids 1 to 233 of human HDAC4
cDNA was inserted into the PCF2H vector (53). In the SR–calcium-calmodu-
lin-dependent protein kinase I (CaMKI) 1-294 construct, kindly provided by
C. D. Kane (Duke University Medical Center, Durham, N.C.), the calmodulin
binding domain (Ca2/CaM independent) was deleted from the cDNA and
therefore CaMKI is constitutively active (29). A cDNA fragment encoding the
active form of murine calcineurin (that lacks the calmodulin binding and auto-
inhibitory domains) was inserted into the pBSIISK() vector under the control
of the myogenin promoter. The Myo 1565-calcineurin expression vector (46) was
produced using a cDNA fragment encoding amino acids 1 to 398 of murine
calcineurin (active form lacking the calmodulin binding and autoinhibitory do-
mains) inserted into the pBSIISK() vector under the control of the myogenin
promoter.
Computer-assisted interspecies analyses of sequences corresponding to the P2
promoter of the AH-J-J locus. For computer-assisted analyses, we used
MacVector sequence analysis software (International Biotechnologies, Inc., New
Haven, Ct.) for Macintosh computers. The Mus musculus counterpart of the P2
promoter sequences used in our analyses were from the National Center for
Biotechnology Information data bank (accession number AF289199). The rat
sequence corresponding to the P2 promoter was obtained after PCR amplifica-
tion of genomic DNA from a Wistar rat (EMBL nucleotide sequence database
accession no. AJ865348). Pustell DNA matrix analyses (16) were performed with
the following parameters: window size  30; strand  both; min % score  55;
jump  1; hash value  6.
Gel shift assay. Nuclear extracts from cell lines or tissues were prepared as
described previously (6, 42). Gel shift reactions were carried out as described
previously (42) by using, as nonspecific competitors, 1 g of poly(dI:
dC)  poly(dI:dC) and 1 g of a single-stranded oligonucleotide. Double-
stranded oligonucleotides used as probes or cold competitors in gel shift exper-
iments are reported in Table 1. Supershift assays were performed by
preincubating nuclear extracts for 20 min with 2 g of commercially available
antibodies specific for MEF-2A (sc-313X), MyoD (sc-304X), and myogenin
(sc-12732X) transcription factors (Santa Cruz Biotechnology, Inc., Santa Cruz,
Calif.) before performing standard binding reactions. Human recombinant
NF-	B p50 and human purified Sp1 (specific transcription factor 1) transcription
factors were purchased from Promega and used in gel shift assays in the presence
of 50 ng of poly(dI:dC)  poly(dI:dC) and 50 ng of a single-stranded cold oligo-
nucleotide.
Site-directed mutagenesis. Mutagenesis was performed by using a
QuikChange site-directed mutagenesis kit (Stratagene). The oligonucleotides
J-MEF-2Mmer, J-GRMmer, and J-E-boxM (Table 1), containing mutant binding
sites, and their complementary sequences were used to inactivate specific binding
in the 159 and 265 pGL3 constructs containing the 159/115 and 265/
115 promoter sequences numbered with respect to the transcription initiation
site. Mutant sequences of the recombinant plasmids were confirmed by DNA
sequencing.
In vivo transfection of rat soleus muscles. Male adult Wistar rats were anes-
thetized with ketamine, and soleus muscles were injected with 60 l of 0.9%
NaCl, containing 50 g of firefly luciferase reporter construct, and 5 g of
pRL-TK vector. Transfected skeletal muscle fibers were obtained by electropo-
ration (36, 40, 48). Pulse protocols, i.e., six pulses of 220 V/cm, pulse durations
of 20 ms, and interpulse delays of 200 ms, were delivered using an ECM 830
Electro Square Porator (BTX; Genetronics, Inc.). Soleus muscles were removed
after 2 days and homogenized in 0.5 ml of passive lysis buffer (Dual Luciferase
reporter assay system; Promega), and luciferase activity was determined.
Statistical analysis. All the data were normally distributed and are presented
as means 
 standard deviations (SD). Statistical differences between groups
were compared using software allowing one-way analyses of variance between
groups. Statistical significance was assumed at P  0.05.
ChIP. For in vitro chromatin immunoprecipitation (ChIP), a ChIP-IT kit
(Active Motif, Carlsbad, Calif.) was used. Two T75 culture flasks of C2C12-DM
cells were fixed for 7 min in minimal cell culture medium containing 1% form-
aldehyde and subsequently rinsed, and the fixation reaction was stopped by
adding 10 ml of glycine stop-fix solution. Cells were collected and centrifuged at
4°C for 10 min at 720  g and resuspended in lysis buffer. After 30 min of lysis
and 10 strokes of Dounce homogenization, nuclei collected by 10 min of cen-
trifugation at 2,400  g were resuspended in shearing buffer. Sonication for ten
cycles (pulses of 15 s at 30% amplitude, with a 30-s rest on ice between pulses)
was performed with Sonics VibraCell VC 130 to prepare DNA fragments ranging
in size from 200 bp to 1,000 bp, followed by centrifugation for 10 min at 13,000
 g. Supernatants were cleared by incubation with salmon sperm DNA-protein
G-agarose beads for 2 h at 4°C. Then 10 l of supernatant was collected and used
as the input. Immunoprecipitation was carried out overnight at 4°C with preim-
mune serum (immunoglobulin G [IgG]) or 3 g of an antibody raised against
MEF-2A (sc-313X; Santa Cruz Biotechnology, Inc.). After centrifugation, wash-
TABLE 1. Double-stranded synthetic oligonucleotides used for gel-shift assays and for the production of mutated P2
promoter/luciferase constructs
Oligonucleotide Source or reference Sequencesb
J-kBmer 5-AACTGGGAAAAGAATCCCGT-3
J-E-box 5-TAGGACCAACTGGGAAAAGAATCCCGT-3
MyoDmer 17 5-CCCCCCAACACCTGCTGCCTGA-3
XDRAbox 16 5-ACCCTTCCCCTAGCAACAGATGCGTCATCT-3
NFkBlgmer sc-2505a 5-AGTTGAGGGGACTTTCCCAGGC-3
Stat1mer sc-2573a 5-CATGTTATGCATATTCCTGTAAGTG-3
Sp1mer 7 5-TGAGGCGTGGCCT-3
J-E-boxM 5-GGAGTTAGCTAGGAAGTATCAGGAAAAGAATCCCG-3
J-E-boxM1 5-TAGGAAGTACTGGGAAAAGAATCCCGT-3
J-EboxM2 5-TAGGACCAACTGGTCGAAGAATCCCGT-3
J-EboxM3 5-TAGGACCAACTGATCAAAGAACTACGT-3
J-GRmer 5-GCACAGTTTGTTCCATTTCA-3
GRETIImer 8 5-AGGATCTGTACAGGATGTTCTAGATCG-3
MEF-2mer 17 5-CTCTAAAAATAACTCC-3
Ets 1mer sc-2549a 5-GGGCTGCTTGAGGAAGTATAAGAAT-3
J-MEF-3mer 5-GTAGTCAGGTCCAATTTCAGT-3
J-MEF-3Mmer 5-TAGTCAGGTCCAAGCTCAGTTCTAGAGG-3
MEF-3mer 50 5-CCTGGTCAGGTTACAGTGG-3
MEF-3Mmer 50 5-CCTGGATATCTATGAGTGG-3
MEF-3MJmer 5-CCTGGTCAGGGCATGAGTGG-3
J-MEF-2mer 5-TAGCCTCTAAAAATAACTGGTGAG-3
J-MEF-2Mmer 5-CATTTAGCCTGTAAACATAACTGGTGAG-3
J-GRMmer 5-GAAAACAAAACTGGCAACGCAGTTTGATACATTTCATTTTTTTTC-3
a Santa Cruz Biotechnology, Inc., Santa Cruz, CA.
b Nucleotide mutations are underlined.
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ing, and elution, the samples were reverse cross-linked by heating at 65°C over-
night and treated with RNase A and proteinase K. DNA was then purified with
the DNA minicolumns provided with the kit, and PCR was performed with
primers 5-TGA GTG GGA AGG GCG CAG ATT-3 and 5-TAC TGC CAG
GAC AAG GGC TCC A-3, designed to amplify a 151-bp product of the mouse
P2 promoter, or primers 5-GGC ATC AGA TCC CAT CAT AGA CA-3 and
5-GGG ACC TAA GTG AGC ATC CTT GA-3, designed to amplify a 155-bp
product of a region about 29 kb upstream of the P2 promoter (negative control),
respectively. The PCR conditions were as follows: 30 cycles of amplification with
15 s of denaturation at 95°C, 30 s of annealing at 66°C, and 20 s of elongation at
72°C. The ChIP assay was performed at least three times. Input DNA was diluted
1:100 to be used as the template for a positive-control PCR.
RESULTS
Transcriptional organization of the human AH-J-J locus
and identification of the transcription initiation site proximal
to the P2 promoter. The structural organization of the human
AH-J-J locus is shown in Fig. 1. The scheme presented is
based both on results previously reported in detail elsewhere
(11, 60) and on newly performed studies employing RT-PCR.
The combination of data obtained by PCR amplification and
sequencing allowed us to define the splicing events (Fig. 1) as
well as the structure of the 5 region of this locus, which
encodes three different proteins, aspartyl--hydroxylase, junc-
tin, and junctate (60). The data obtained indicate that the first
and second exons are mutually exclusive when mature mRNAs
are produced. Moreover, the use of different splice donors has
been shown to be involved in the generation of protein diver-
sity by alternative splicing (see lower part of Fig. 1). Our results
are in agreement with data from Dinchuk et al. (11) obtained
with a homologous mouse system and suggest that at least two
promoter sequences (tentatively identified as P1 and P2) are
present in the 5 region of the AH-J-J locus. In this study, we
focused our attention on the P2 promoter, which directs tissue-
specific expression of the AH-J-J locus starting from exon 2.
The RT-PCR analysis presented in the upper part of Fig. 2A
shows that by using an exon 2-specific forward primer we are
able to analyze all the transcripts starting from the P2 pro-
moter. In the case of human tissues and cells we used primers
located in the second and third exons, and in the case of
murine C2C12 cell line we used primers located in the second
and fifth exons, which exhibit a high level of homology in
comparisons of human and mouse sequences. The results ob-
tained with kidney, brain, adrenal gland, liver, heart, skeletal
muscle, the RD cell line, C2C12-GM cells (C2C12 cells cul-
tured in growth medium), and C2C12-DM cells (C2C12 cells
cultured in differentiation medium) show that transcription
directed from the P2 promoter is tissue specific. Among the
analyzed human tissues, high-level transcription was present
only in skeletal muscle, cardiac muscle, and brain (Fig. 2A,
lanes f, e, and b). P2 directed transcription was found in RD
cells, C2C12-GM, and C2C12-DM cells, with the highest level
of expression in differentiated C2C12 cells (Fig. 2A, lane i).
Since the transcription initiation site has not been previously
described in detail, we also performed 5 RACE to precisely
map the origin of transcription. This experiment was per-
formed on total RNA isolated from RD cells and human adult
skeletal muscle. As shown in Fig. 2B, one band is evident
following electrophoresis of 5 RACE products in both cases
(lanes m and n). This band was directly sequenced or cloned
and then sequenced, giving identical results in both cases. The
sequence of the 5 RACE products is shown in Fig. 2C and
allows mapping the transcription initiation site, which is indi-
cated by a solid arrow. Accordingly, all the nucleotide se-
quences located upstream from this site were considered po-
tential regulatory regions belonging to the P2 promoter.
Transcriptional activity of the AH-J-J P2 promoter. A
PCR-generated fragment of the P2 promoter spanning the
region from nucleotide 686 to nucleotide 115 with respect
to the transcription initiation site was cloned into the firefly
luciferase reporter vector pGL3-basic, sequenced, and used to
generate progressive deletions for transient transfection exper-
iments. As target DNA, the human genomic BAC 1 clone was
used (60). The nine nested deletion constructs shown on the
left side of Fig. 3 were generated as described in the Materials
and Methods section. Each recombinant plasmid DNA was
then transiently transfected into cells of the myogenic C2C12
cell line (27). The vector pGL3-basic, which has no promoter,
was used as the control. From the data obtained, we are able to
draw the following conclusions. First, the 88 construct does
not induce luciferase activity (Fig. 3). Second, luciferase activ-
ity was detectable using the 48 construct and increased to the
maximum levels with the 159 construct. These data suggest
that cis-acting elements activating transcription are present
between 159 and 88. Furthermore, the luciferase activity
remains at these high levels up to construct 265. Third, lu-
FIG. 3. Promoter activity of serial deletion constructs of the AH-J-J 686 to 115 nucleotide sequence (the P2 transcription initiation site
is referred as 1). C2C12 cells were transfected with sequentially deleted reporter constructs (represented in the left side of the figure). Transient
transfection and luciferase assays were performed in triplicate, and the data were normalized to Renilla luciferase activity and reported as a ratio
to pGL3-basic RLU (means 
 SD). pGL3-basic is a firefly luciferase (LUC) reporter vector with basal promoter activity.
VOL. 25, 2005 MEF-2 ACTIVATES JUNCTIN AND JUNCTATE PROMOTER 3265
ciferase activity was present in the 368 and 526 constructs
but at a lower level (P 0.002 when368 and265 constructs
are compared and P 0.0008 when 526 and 368 constructs
are compared), suggesting the presence of cis-acting elements
inhibiting transcription between 526 and 265. The 526,
561, and 686 constructs exhibited similar activity levels.
In vivo experiments were performed on male adult Wistar
rats. Soleus muscles were injected with the same firefly lucif-
erase reporter constructs, and transiently transfected skeletal
muscle fibers were obtained by in vivo administration of elec-
tric pulses as described elsewhere (48, 40). After 2 days, soleus
muscles were removed and luciferase activities were deter-
mined. As shown in Fig. 4, we obtained patterns of reporter
activity for soleus muscle very similar to those obtained with
C2C12 cells. In particular, constructs 368, 265, and 220
sustained a high level of transcription. Interestingly, lower lev-
els of transcription were obtained using constructs 174 and
159 (P  0.0001 in comparisons of constructs 220 and
174; P  0.007 in comparisons of constructs 174 and
159). Furthermore, it should be noted that construct 48
does not support efficient transcription. These data suggest
that several cis-acting elements, present between 48 and
220, are involved in the up-regulation of transcription in this
experimental system. In addition, as for the experiment em-
ploying C2C12 cells (Fig. 3), the luciferase activity sustained by
constructs 686, 561, and 526 was significantly lower (P 
0.003 in comparisons to construct 368).
For the next series of experiments we concentrated on the
265 to 88 sequence, since this exhibited the highest induc-
tion of luciferase activity in both systems.
Identification of sequences putatively recognized by nuclear
factors within the 265 to 1 P2 region of the AH-J-J locus.
In accordance with the evidence that the region downstream of
265 contains the minimal promoter, the human P2 sequence
265 to 123 was analyzed to find interspecies homologies
with mouse and rat counterparts (Fig. 5A). Interspecies ho-
mology phylogenetic searching allows identification of evolu-
tionarily conserved regions possibly important for gene regu-
lation, as demonstrated in several research papers (3, 5, 16).
This sequence homology study (Fig. 5A) allowed the identifi-
cation of four regions (HR1, HR3, HR4, and HR5) conserved
in mouse, human, and rat sequences and one (HR2) conserved
in rat and human sequences. These homologies are analyzed in
detail in Fig. 5B. When this analysis is combined with a search
for transcription factor binding sites using the TF search pro-
gram, we identified within these conserved regions sequences
homologous to the glucocorticoid receptor element (GRE)
(242 to 224) (8), c-Myb/MyoD (173 to 164) (47, 50),
NF-	B (161 to 152) (41), and MEF-2 (80 to 65) (17)
consensus boxes. The location of putative transcription factor
binding sites, together with the transcription initiation site, is
shown in Fig. 5C. The52 to32 sequence, underlined in Fig.
5C and relative to HR5, is highly homologous to MEF-3 bind-
ing sites present in a large number of skeletal muscle-specific
transcriptional enhancers and promoters (24, 50, 56).
These boxes, which could be fairly conserved through evo-
lution, were further analyzed by molecular biology ap-
proaches. To demonstrate protein-DNA interactions at these
sites, band shift assays were performed. Table 1 shows the
synthetic and mutant oligonucleotides used for band shift ex-
periments. Figure 6 shows representative examples of the re-
sults obtained using the J-E-box and J-kBmer, J-GRmer, and
J-MEF-3mer 32P-labeled double-stranded oligonucleotide
probes.
To verify the specificity of the interactions, competitive ex-
periments were performed using (i) unlabeled unrelated oli-
gonucleotides, (ii) homologous sequences recognized by
known transcription factors, or (iii) mutations of the binding
site under investigation.
The representative data shown in Fig. 6 were obtained from
experiments performed after preliminary screening of nuclear
extracts from different cell lines (C2C12, RD, and H9c2) to
identify nuclear extracts containing the highest levels of the
protein(s) able to interact with the oligonucleotides under in-
vestigation.
With respect to the J-E-box sequence spanning the region
from nucleotide 177 to nucleotide 151, in addition to the
canonical E-box (CANNTG) (50), the J-kB sequence is
present, exhibiting 67% homology with the asymmetric NF-	B
binding site (41). The first conclusion that can be drawn from
the results presented in lanes 2 and 3 of Fig. 6 is that at least
two complexes are able to bind to the J-E-box probe (white and
black arrows). In addition, the J-E-box cold oligonucleotide is
able to inhibit both binding activities (Fig. 6, lanes 4 and 9),
while the addition of cold J-kBmer (lacking the E-box signal)
inhibits only the generation of the fast mobility complex (Fig.
6, lane 8), demonstrating that E-box binding activity generates
the lower-mobility retarded band. As far as characterization of
FIG. 4. Promoter activity of serial deletion constructs of the AH-J-J 686 to 115 nucleotide sequence in soleus muscle of adult rats. Soleus
muscles were injected with 50 g of serial deletion constructs, and the calf was exposed to electrical pulses. At 48 h after transfection each muscle
was homogenized in lysis buffer and assayed for luciferase activity. Transient transfection and luciferase assays were performed in triplicate, and
the data were normalized to Renilla luciferase activity and reported as a ratio to pGL3-basic RLU (means 
 SD). pGL3-basic is a firefly luciferase
(LUC) reporter vector with basal promoter activity.
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binding activity to the E-box site of the J-E-box probe is con-
cerned, we can exclude a direct involvement of the transcrip-
tion factor MyoD, since cold MyoDmer is unable to inhibit the
formation of the low-mobility complex (Fig. 6, lane 5). As
expected, the unrelated Sp1mer was also unable to inhibit
J-E-box-protein interactions (Fig. 6, lane 6). Accordingly, (i)
when 32P-labeled MyoDmer was employed, a different pattern
of retarded bands was obtained and (ii) supershift experiments
with an antibody against MyoD did not show any alteration of
the interaction of nuclear factors with the J-E-box (data not
shown). These experiments suggest that nuclear factors other
than MyoD bind to the J-E-box element, with the consequent
generation of the lower-migrating band. As far as the charac-
terization of the binding activity to the NF-	B-like site of the
J-E-box probe is concerned, Fig. 6 (lanes 14 to 19) shows that
while competitors containing binding sites for Stat1 and X-box
binding proteins are unable to suppress binding of nuclear
factors to J-kBmer probe (Fig. 6, lanes 17 and 19), NFkBIgmer
suppresses this binding (Fig. 6, lane 18). As expected, J-kBmer
and J-E-box are also strongly active as competitors (Fig. 6,
lanes 15 and 16).
To characterize the interplay between nuclear factors and
the overlapping sites present within the J-E-box, mutant oli-
gonucleotides were used. Figure 6 (lanes 7 to 13) shows that
addition of cold mutants altering the conserved E-box se-
quence (J-kBmer and J-E-boxM1) did not inhibit the formation
of the lower-migrating band, when 32P-labeled J-E-box was
mixed to nuclear factors from C2C12 cells (Fig. 6, lanes 8 and
11). However, the flanking sequences are also expected to play
a role, since the J-E-boxM2 and the J-E-boxM3 mutants do not
FIG. 5. (A) Dot-matrix comparison of the human AH-J-J P2 pro-
moter 265 to 123 nucleotide sequence performed with respect to
the murine (up; National Center for Biotechnology Information data
bank accession number AF289199) and rat (down; EMBL Nucleotide
Sequence Database accession number AJ865348) counterpart (1 to
388 from ATG) by the use of MacVector sequence analysis software.
Lines represent homologies between the analyzed sequences; homol-
ogy regions have been identified as HR1, HR2, HR3, HR4, and HR5.
(B) Nucleotide sequences present within the HR regions identified
(^, conserved nucleotide; -, nonconserved nucleotide). (C) 265 to
7 P2 promoter sequence. Dark lines and boxes indicate the oligonu-
cleotides used in gel shift assays (Table 1) and the sequences homol-
ogous to transcription factors binding sites found within the conserved
region depicted in panel A. Homologies were obtained by TF-
SEARCH version 1.3 software and are as follows: GR-box (glucocor-
ticoid response element), 89%; c-Myb and MyoD boxes, 88 and 80%,
respectively, with J-E-box; NF-	B box, 67% with J-kBmer; and MEF-2
box, 90%. The arrow indicates the P2 transcription initiation site (1).
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inhibit the formation of the lower-migrating band (Fig. 6, lanes
12 and 13). As expected, competition was always observed with
the wild-type J-E-box (Fig. 6A, lane 9). As far as mutations
affecting the NF-	B-like sequence are concerned, those affect-
ing the conserved CTG and AAA stretches of the NF-	B
binding sites suppress the binding generating the fast-migrat-
ing band. In fact, the oligonucleotides J-E-boxM, J-E-boxM2,
and J-E-boxM3 do not bind to NF-	B-like factors, while the
J-E-boxM1, carrying an intact NF-	B binding site, interacts
with transcription factors generating the fast-migrating com-
plex (Fig. 6, lane 11). These results give strong evidence that
proteins belonging to the NF-	B superfamily interact with the
NF-	B sites present within the AH-J-J P2 promoter. This is
conclusively shown by the experiment reported in Fig. 6B,
FIG. 6. Binding of nuclear factors to the AH-J-J promoter 2. (A and B) Band shift assays performed using J-kBmer (170 to 151), J-E-box
(177 to 151), and NFkBlgmer and MyoDmer (Table 1) probes and 2 to 3 g of nuclear extracts (NE) from RD, C2C12-DM-8 h (C2C12 cells
were induced to differentiate in DM for 8 h and a nuclear extract was prepared), and H9c2 cells or 0.05 g of human recombinant p50 and purified
human Sp1 transcription factors (Promega), as indicated. (-), probe was incubated with nuclear extracts in the absence of competing oligonucle-
otides. (C and D) Band shift assays performed using J-GRmer (241 to 222), J-MEF-3mer (52 to 32), and MEF-3mer (Table 1) probes and
2 to 3 g of nuclear extracts (NE) from C2C12-GM and RD cell lines. (-), probe was incubated with nuclear extracts in the absence of competing
oligonucleotides. In this figure, competing oligonucleotides (Table 1) were added at a 100-fold molar excess. Arrows indicate the specific
complexes.
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showing that the recombinant p50 NF-	B protein binds to the
J-kBmer (lane 21). As expected, the binding efficiency is lower
than that displayed by the symmetric Igk NF-	B site (lane 22),
as already reported in several studies (62). No binding of pu-
rified Sp1 transcription factor to the J-kBmer was found (lane
20).
As far as the interactions of J-GRmer with nuclear extracts
from C2C12 cells are concerned, the data shown in Fig. 6C
demonstrate that the binding is specific, since competition was
clearly observed with unlabeled J-GRmer (lane 27) but not with
the unrelated oligonucleotides carrying the Ets 1 and MEF-2
binding site (lanes 28 and 26). Surprisingly, the tyrosine-ami-
notransferase II (TATII)-GRE double-stranded oligonucleo-
tide (8) containing the consensus GRE failed to compete (Fig.
6, lane 25); thus, factors that interact with J-GRmer should be
further characterized to establish their relationship, if any, with
canonical GRE binding proteins. This result was reproducibly
obtained in several experiments, using high amounts of com-
petitor GRETIImer. Control experiments demonstrated high
efficiency of binding of 32P-labeled GRETIImer to nuclear ex-
tracts. Opportune mutations introduced in J-GRmer (J-GRM-
mer; see Table 1 for nucleotide sequences) completely abolish
the interaction with nuclear factors (data not shown).
Binding to the J-MEF-3mer (Fig. 5C and Table 1) is shown
in Fig. 6D, which depicts representative results obtained using
the rhabdomyosarcoma RD cell line, expressing MEF-3 bind-
ing factors at high levels. The gel shift pathways obtained using
32P-labeled J-MEF-3mer and MEF-3mer (carrying a functional
MEF-3 binding site present in the promoter sequence of the
slow/cardiac troponin C) (50) are identical (Fig. 6D, lanes 34
and 35). In addition, the binding to 32P-labeled J-MEF-3mer is
specifically competed by both cold MEF-3mer and J-MEF-3mer
(Fig. 6, lanes 31 and 29). Furthermore, mutations suppressing
binding to J-MEF-3mer (lanes 30, 32, and 33) also affect MEF-
3mer interaction with nuclear extracts (data not shown). As
expected, no inhibition of binding of nuclear factors to MEF-
3mer and J-MEF-3mer is obtained with unrelated oligonucleo-
tides carrying SRE or sequences recognized by the Sp1, AP-1,
Stat1, and C/EBP transcription factors (data not shown).
Taken together, these results support our hypothesis that
J-MEF-3mer and MEF-3mer bind to the same nuclear factors.
MEF-2 transcription factors bind to the MEF-2 binding
sites of the P2 promoter of the AH-J-J locus. Due to the
important role of MEF-2 in muscle-restricted gene expression,
the interactions of nuclear proteins with respect to the MEF-2
binding site of the P2 promoter sequences of the AH-J-J
locus were studied in great detail (19). Since J-MEF-2mer con-
tains sequences highly homologous to those recognized by the
MEF-2 family factors (including MEF-2A, -B, -C, and -D) (4,
23, 33, 70), competition experiments were first performed us-
ing the MEF-2mer oligonucleotide, carrying a canonical
MEF-2 binding site (17). Cold MEF-2mer is able to inhibit
binding under these experimental conditions (Fig. 7A, lanes 5
and 6). A two-base mutation in the binding site of J-MEF-2mer
abolishes formations of gel shift complexes (Fig. 7A, lanes 8
and 10).
Figure 7B demonstrates that the MEF-2 binding activity is
strongly induced in association with muscle differentiation. In
this experiment muscle differentiation was obtained after treat-
ment of C2C12 cells with DM for 3 days.
In addition, supershift experiments were performed using
monoclonal antibodies against MEF-2 and nuclear extracts
from C2C12-DM cells, demonstrating that addition of the an-
tibody induces a clear supershift (Fig. 7C, lanes 16 and 17).
Since this commercial MEF-2A specific antibody cross-reacts
with other members of the MEF-2 family, we can conclude that
MEF-2 family nuclear factors binds to the J-MEF-2mer probe.
An antibody against myogenin, as expected, failed to induce
supershift (Fig. 7C, lane 18).
The experiments shown in Fig. 7C were performed in rep-
FIG. 7. Identification of MEF-2 family nuclear factors that interact
with the AH-J-J promoter 2. (A and B) Band shift assays were
performed using J-MEF-2mer probe (84 to 61) or mutant probe
(mp, J-MEF-2Mmer) (Fig. 7A, lane 8) (Table 1) and 2 g of nuclear
extracts (NE) from RD (A) or C2C12-GM and -DM (B) cells, cultured
in growth and differentiation medium, respectively. (-), probes were
incubated with nuclear extracts in the absence of competing oligonu-
cleotides. Competing oligonucleotides (Table 1) were added at a 100-
fold molar excess with the exception of lanes 3 and 5 (50-fold molar
excess). (C and D) Band shift and supershift assays were performed
using J-MEF-2mer probe and 2 g of NE from C2C12-DM or 8 g of
NE from soleus muscle. (-), control samples in the absence of com-
peting oligonucleotides or antibodies; probe was incubated with nu-
clear extracts in the presence of the indicated competing oligonucle-
otides (at a 100-fold molar excess) or in the presence of antibodies
(Ab) against MEF-2 family members (1 to 2 g) or against myogenin
(2 g). In this figure, arrows indicate the specific complexes; arrow-
heads indicate complexes supershifted by antibody.
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licate by the use of nuclear extracts from rat soleus muscle.
Despite the fact that the binding efficiency in this case is lower
(compare panels C and D of Fig. 7), the results are consistent
with those obtained using C2C12 cells.
Studies of MEF-2 binding to wild-type and mutated cis el-
ements: effects on transcription. The finding that MEF-2-re-
lated factors bind to the J-MEF-2 box present in the 80 to
65 region of the P2 promoter of the AH-J-J locus is of great
interest for the known tissue-specific up-regulating functions of
MEF-2 (37, 9) on the one hand and for the promoter activity
of the region between159 and the transcription initiation site
on the other. Since this region contains the MEF-2 binding site
(Fig. 5C), it could be considered the “minimal” P2 promoter
sequence (Fig. 3 and Fig. 4).
The main goal of the experiment described in Fig. 8 was to
confirm the involvement of MEF-2 in the transcriptional reg-
ulation of the AH-J-J locus. We first designed a J-MEF-2mer
mutant (J-MEF-2Mmer) unable to bind the MEF-2 family fac-
tors. This was demonstrated by the finding that no retarded
bands are generated following incubation of nuclear factors to
a J-MEF-2Mmer probe (Fig. 7A, lane 8). In agreement, mu-
tated cold J-MEF-2Mmer failed to inhibit MEF-2 proteins and
J-MEF-2mer interactions (Fig. 7A, lane 10). Accordingly, we
produced a159 pGL3 deletion construct carrying this MEF-2
binding site mutation (159 MEF-2 box mut). When the 159
mutant construct was used to transfect C2C12 cells, a decrease
in luciferase activity (relative to the wild-type 159 construct)
was detected (P 0.001) (Fig. 8A). To further confirm the role
of MEF-2 in the regulation of the promoter we performed in
vivo experiments on soleus muscles of male adult Wistar rats.
Soleus muscles were injected with the same firefly luciferase
reporter constructs shown in Fig. 8A, and luciferase activity
was determined. The results are shown in Fig. 8B and conclu-
sively demonstrate that when the 159 mutant construct is
used, a highly significant decrease (over 65%) of luciferase
activity is obtained with respect to the wild-type construct (P
0.0008).
Finally, to unambiguously confirm the role of MEF-2 in the
transcription activity directed by the P2 promoter, we used a
recombinant plasmid carrying a MEF-2A cDNA under the
control of the cytomegalovirus promoter and directing high
levels of expression of MEF-2 in transfection experiments (4,
68). When C2C12-DM cells were cotranfected with the 159
construct and the MEF-2A-expressing plasmid, a sharp in-
crease in luciferase activity was observed (Fig. 8C). This result
was reproducibly obtained in six independent experiments (P
 0.005). This increase was only barely detectable using the
159 construct carrying the mutated MEF-2 binding site de-
scribed (lower part of Fig. 8C; 159 MEF-2 box mut). The
effects of transfection with the MEF-2A-expressing vector
were also detectable using other cell lines, such as HeLa cells
(Fig. 8D).
Taken together, these results demonstrate an involvement of
the MEF-2 signal and MEF-2 transcription factors in transcrip-
tional regulation of the AH-J-J locus.
Transcriptional effects of mutations of MEF-2 box, GR box,
or E-box. To obtain information about the importance of some
of the identified transcription factor signals of the P2 pro-
FIG. 8. Transcriptional effect of mutation in the MEF-2 binding site of the AH-J-J promoter 2. (A) C2C12-GM cells were transfected with
wild-type (159 and 48) and MEF-2 binding site mutant (159 MEF-2 box mut) AH-J-J P2 promoter reporter constructs (represented in the
left side of the figure). Transient transfection and luciferase assays were performed in triplicate, and the data were normalized to Renilla luciferase
activity and are reported as ratios (means 
 SD) to the pGL3-basic firefly luciferase (LUC) reporter vector. (B) The same constructs presented
in panel A were transiently transfected in rat soleus muscles as described for the experiment whose results are presented in Fig. 4. (C and D) The
wild-type and mutant 159 constructs whose results are presented in panels A and B were utilized in the absence (black bars) or in the presence
(white bars) of MEF-2A expression vector for C2C12-GM (C) and HeLa (D) cells transfections.
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moter, we next compared the effects of mutations in the
MEF-2 box to those suppressing binding activity of nuclear
factors to the GR and E boxes. For this purpose, we designed,
synthesized, and tested mutants of GR box and E-box sup-
pressing protein binding to the relative 32P-labeled mers (see
nucleotide sequences in Table 1) and produced three 265
constructs carrying the mutated GR box, E-box, and MEF-2
box, respectively. The activity of these constructs was com-
pared to that of the wild-type reporter plasmid after transfec-
tion of soleus muscle of adult Wistar rats (Fig. 9).
The results of this experiment clearly indicate that in soleus
muscle of adult Wistar rats all mutated constructs exhibited a
decreased ability to stimulate luciferase activity, indicating that
proteins binding to these boxes play a role in up-regulating
transcription (P  0.0005 for GR box mut; P  0.003 for E-box
mut; P  0.00002 for MEF-2 mut). When the experiment was
conducted with C2C12-GM cells the inhibition of transcription
with the MEF-2 mut construct was lower than that found in
C2C12-DM cells (data not shown), suggesting that the role of
MEF-2-related proteins in regulating the expression of the
AH-J-J locus is mostly evident in differentiating cells.
MEF-2 transcription factors bind chromatin of the P2 pro-
moter. The recently described chromatin immunoprecipitation
(ChIP) technology allows formally demonstration in intact
cells of the interaction of a given DNA binding protein with
promoter region identified by specific PCR primers.
Accordingly, after formaldehyde cross-linking, the chroma-
tin isolated from C2C12-DM cells was sonicated and immuno-
precipitated with an anti-MEF-2A antibody. PCR was per-
formed on purified DNA by the use of primers amplifying the
AH-J-J P2 promoter. After 30 PCR cycles, amplification of
the AH-J-J P2 promoter was obtained using only DNA from
the MEF-2A-specific immunoprecipitates as the substrate (Fig.
10). No PCR product was obtained using unrelated IgG im-
munoprecipitation controls. As expected for the ChIP assays,
both control IgG and anti-MEF-2 antibody immunoprecipi-
tates contained equal amounts of negative-control sequences
that were able to be PCR amplified, but only when the PCR
was conducted for a high number of cycles (more than 35; data
not shown).
Effects of HDACs and CaMK on MEF-2-directed tran-
scription. Several studies have demonstrated a strong interplay
between MEF-2 and histone deacetylases (HDACs) (33, 37,
43), as well as between MEF-2 and Ca2/calmodulin-depen-
dent protein kinases (CaMKI and CaMKIV) (51). In this re-
spect, it was recently shown by several laboratories that MEF-2
interacts with class II HDACs and that this interaction leads to
repression of the transcriptional activity of MEF-2 (33, 37).
CaMKI modulates the interactions between HDACs and
MEF-2; in fact, activation of CaMKI leads to HDAC phos-
phorylation and dissociation of MEF2/HDAC complexes (33).
Accordingly, we determined the effects of plasmids express-
ing HDAC4 (43) and CaMKI (29) on luciferase activity of the
159 construct.
In the first set of experiments, we used three expression
vectors, one for full-length HDAC4 (43) and the other two for
mutated HDAC4 lacking either the enzymatic activity domain
( catalytic d.) (53) or the MEF-2 binding domain ( MEF-2
bind. d.).
The results shown in Fig. 11A clearly demonstrate that when
the C2C12-DM cells are cotransfected with the 159 con-
struct, with MEF-2A- and HDAC4-expressing plasmids a
sharp decrease of luciferase activity is observed with respect to
transfections carried out with the 159 construct and with
FIG. 9. Effect on promoter activity of mutations in the GR box, E-box, or MEF-2 binding site of the AH-J-J 265 P2 promoter reporter
construct. Rat soleus muscles were transiently transfected with wild-type and specific DNA binding site mutants of the AH-J-J 265 P2 promoter
reporter construct as described for the experiments whose results are presented in Fig. 3 and 4.
FIG. 10. Chromatin immunoprecipitation with MEF-2A-specific
antibody. C2C12-DM (in differentiation medium for 72 h) cells were
formaldehyde cross-linked and processed for ChIP assays with anti-
bodies (Abs) against MEF-2A (Santa Cruz) or IgG (as the control).
PCR products, obtained with primers flanking the MEF-2 binding site
of the AH-J-J P2 promoter or with primers amplifying a region 29 kb
upstream of the P2 promoter (negative control), were analyzed by gel
electrophoresis. Input, control sample before the immunoprecipita-
tion. M, pUC Mix Marker 8 (Fermentas).
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MEF-2A. Cotransfections with plasmids encoding mutated
HDAC4 (i.e., defective in catalytic activity or in MEF2 bind-
ing) show an at least partial restoration of reporter activity.
This partial effect is not surprising, since it known that HDAC4
and HDAC5 lacking the catalytic domain and even the MEF-2
binding motifs are still capable of inhibiting MEF-2 dependent
transcription (43).
To further support the hypothesis that the activity of the P2
promoter depends on MEF-2 activity possibly regulated by
HDAC4, the experiment depicted in Fig. 11B was performed.
In this experiment, the 159 construct was used in combina-
tion with plasmids expressing MEF-2A and CaMKI or cal-
cineurin in C2C12-DM cells. In both cases, an increase in
luciferase activity was obtained (Fig. 11B). A sharp increase in
luciferase activity was obtained using C2C12-GM cells trans-
fected with the CamKI-expressing vector (Fig. 11C). This in-
crease is not obtained in the presence of expression vectors
carrying full-length HDAC4. Vectors carrying HDAC4 lacking
MEF-2 binding domains were significantly less effective (Fig.
11C).
DISCUSSION
The aim of the present paper was to investigate one of the
two putative promoter sequences regulating the transcription
of the AH-J-J locus. We have been able to (i) define the
transcription initiation site of junctin by RACE, (ii) identify a
5 untranscribed region, possibly involved in the regulation of
the expression of the AH-J-J locus, and (iii) identify tran-
scriptional factors and determine their functional activity in
this region in a set of cell lines and also in an in vivo model
such as rat soleus muscle.
The major conclusions of the present work are the following:
(i) the P2 promoter of the AH-J-J locus contains sequences
recognized by known transcription factors, such as MEF-2,
MEF-3, NF-	B, as well as signals for other yet-to-be-charac-
terized proteins; (ii) cis elements were identified with negative
and positive effects on transcription; (iii) the minimal promoter
is located within 159 nucleotides from the transcription ini-
tiation site; and (iv) the nuclear transcription factor MEF-2 is
required for transcriptional activation.
The involvement of MEF-2 in the transcriptional activity of
the P2 promoter of the AbH-J-J locus is demonstrated by
several convergent approaches, including supershift experi-
ments (Fig. 7), in vivo chromatin immunoprecipitation (ChIP)
(Fig. 10), and cotransfection of C2C12-DM cells with a plasmid
carrying the P2 AH-J-J minimal promoter and an expression
plasmid carrying MEF-2 cDNA under the control of a cyto-
megalovirus promoter. Moreover, the idea of the involvement
of MEF-2 in transcriptional regulation of the AH-J-J locus is
further sustained by experiments employing constructs carry-
ing mutated MEF-2 DNA binding sites. These promoters were
found to be less active in sustaining transcription of the lucif-
erase reporter gene both in vitro and in vivo (Fig. 8 and 9). In
addition, in striated muscle the promoter containing a mutated
MEF-2 binding site is more affected in its transcriptional ac-
tivity than promoters carrying mutated GR- or E-boxes, sug-
gesting that nuclear proteins binding to the MEF-2 site play a
major transcriptional role in this system. This conclusion sup-
ports the hypothesis that the muscle-specific MEF-2 DNA
FIG. 11. Effect of HDAC4, CamKI, and calcineurin on P2 promoter activation by MEF-2A. (A) C2C12-DM cells were transfected with the
159 construct in the presence of MEF-2A expression vector (white bars) and the indicated HDAC4 expression constructs (full-length, wild-type
HDAC4;  catalytic d., HDAC4 lacking the catalytic domain;  MEF-2 bind. d., HDAC4 lacking the MEF-2 binding domain). Transient
transfection and luciferase assays were performed in triplicate, and the data were normalized to Renilla luciferase activity and are reported as ratios
(means 
 SD) to the pGL3-basic firefly luciferase (LUC) reporter vector. (B) The same experiment whose results are presented in panel A was
performed with the 159 construct, the MEF-2A expression vector, and the indicated CamKI and calcineurin expression constructs.
(C) C2C12-GM cells were transfected with the 159 construct alone or in the presence of CaMKI expression vector and the indicated HDAC4
expression constructs.
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binding activity is sufficient to reach maximum levels of tran-
scription (Fig. 8 and 9). However, reproducible differences
should be underlined when in vivo (Fig. 4) and in vitro (Fig. 3)
systems are compared; first, the severalfold induction of lucif-
erase activity in rat soleus muscles is much higher that that
found in C2C12 cells. This is not unexpected, given our RT-
PCR data showing that the transcription directed by the P2
promoter is far more sustained in adult muscles than in C2C12
cells. Furthermore, the 48 construct does not sustain tran-
scription in the in vivo system; in contrast, it is active in C2C12
cells. These discrepancies could be due to several factors, such
as differences in the differentiation states of the target cells,
species, transfection efficiency, and/or transfection strategy.
Our data are in agreement with recent literature showing
binding interactions and functional interplay between MEF-2
and histone deacetylase 4 and 5 (33). Accordingly, transfec-
tions with constructs expressing HDAC4 decrease transcrip-
tion directed by the P2 AH-J-J promoter in the absence or in
the presence of transfection with MEF-2-expressing vectors.
These results are consistent with most of the available liter-
ature on MEF-2 biological functions. For instance, myogenesis
in mouse C2 cells is inhibited by double-stranded phosphoro-
thioate oligodeoxynucleotides containing binding sites recog-
nized by proteins belonging to the MEF-2 superfamily. Expo-
sure of C2 myoblasts to doxorubicin had a profound effect on
the expression of regulatory genes critical to the myogenic
differentiation program (30); levels of mRNAs for MyoD and
myogenin were dramatically reduced. In addition, there was
diminished DNA binding activity of the muscle-specific tran-
scription factor MEF-2. These data and other experimental
evidence indicate that MEF-2 is involved in the activation of
muscle-specific genes, including rat myosin light chain 2 slow,
human myoglobin, rat muscle creatine kinase, mouse troponin
C slow, and human beta enolase (14, 15, 20, 26, 50). In addi-
tion, MEF-2 has been proposed to serve as a nodal point in the
mechanisms by which motor nerves control the program of
gene expression in skeletal muscle fibers and in the pathway
leading to cardiac hypertrophy. High levels of mRNA expres-
sion of both junctin and junctate have been observed in cardiac
muscle (11, 60). Interestingly, there is experimental evidence
demonstrating that the trans-activator factor MEF-2 is in-
volved in the regulation of gene expression in cardiac tissue.
MEF-2 would act as a downstream effector of calcium-depen-
dent signaling mediated by calcineurin (32). Recent studies
have demonstrated that calcineurin modulates gene transcrip-
tion not only in cardiac muscle but also in skeletal muscle (65).
The calcineurin-dependent signaling has been associated with
the adaptive mechanism of cardiac muscle in responses to
hypertrophic agonists such as angiotensin II and phenylephrine
(45, 13). These two agonists activate calcium release from the
cardiac junctional sarcoplasmic reticulum, and the transient
increase of calcium levels would in turn activate calcineurin
and its downstream effectors NFAT and MEF-2.
In conclusion, the most interesting result emerging from our
study is that the calcium-dependent transcriptional factor
MEF-2 activates the promoter of two proteins of the junctional
sarcoplasmic reticulum membrane in addition to other muscle-
specific genes. In agreement with these considerations, trans-
fections with CamKI- and calcineurin-expressing vectors aug-
ment transcription directed by the AH-J-J P2 promoter.
These data are well in agreement with observations published
elsewhere suggesting that the calcineurin-mediated removal of
phosphate groups from MEF-2 augments the potency of the
transcriptional activation domain of MEF-2 fused to a heter-
ologous DNA binding domain (65). Whether the observed
effect of calcineurin is due to this mechanism of action or to
others, including dephosphorylation of NFAT, remains to be
determined (37). In respect to CaMKI, it is known that phos-
phorylation of HDACs by Ca2/calmodulin-dependent pro-
tein kinases leads to dissociation from MEF-2 and increased
MEF-2-dependent transcriptional activity.
Note that the relationship between calcium signaling and
regulation of the expression of the AH-J-J locus is not re-
stricted to MEF-2 and other calcium-dependent transcription
factors but also involves the biological functions of the proteins
encoded by the AH-J-J locus. In this respect, junctin and
junctate are localized in a key membrane compartment in-
volved in the generation of the calcium signal both in skeletal
and cardiac muscle.
To our knowledge this is one of the few cases in which a
calcium-dependent transcriptional factor influences the ex-
pression of gene involved in calcium signaling.
The finding that MEF-2 and MEF-3 binding sites are
present in the P2 promoter of the AH-J-J locus and the data
supporting an involvement of MEF-2 in the transcription di-
rected by the P2 promoter are in strong agreement with the
muscle-specific expression of junctin and junctate, as reported
by several laboratories, including ours. Of great interest is the
finding that no homology was found between the P2 promoter
sequences and the sequences present in the upstream P1 pro-
moter, as conclusively demonstrated by the results of homol-
ogy studies performed using MacVector sequence analysis
software. In particular, neither MEF-2 nor MEF-3 binding
sites are present, while we found Sp1, AP-2, C-EBP, and
GATA-1 functional binding sites; this finding supports the
hypothesis that this P1 promoter, unlike the P2 promoter,
exhibits a strong and broad transcriptional activity (G. Feri-
otto, F. Zorzato, and R. Gambari, unpublished data).
Therefore, this gene cluster appears to be very appealing for
studies of the transcriptional and posttranscriptional regula-
tion of gene expression in eukaryotes, as has been already
reported for different eukaryotic gene systems (2, 31), includ-
ing acetylcholinesterase (38), Pcdh-gamma (63), protocadherin
alpha and gamma (59), regulator of G protein signaling GAIP/
RGS19 (66), chondrolectin (64), and stromelysin 3 (34).
Our results do not conclusively address the involvement of
other factors in the transcription of the AH-J-J locus, despite
the fact that E-box- and GRE-like activities are important for
transcription of this locus. In addition, our data do not exclude
involvements of protein-protein interactions. This study could
be of interest due to strong evidence demonstrating that
MEF-2 proteins interact with other transcription factors, in-
cluding members of the MyoD family of transcriptional acti-
vators, to synergistically activate gene expression (10). Simi-
larly, physical interactions between Sp1 and MEF-2 were
demonstrated by immunological detection of both proteins in
DNA binding complexes formed in vitro by nuclear extracts
(20).
In conclusion, the data reported here on the functional char-
acterization of the junctin-junctate promoter in vitro and in
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vivo suggest the possibility that the calcineurin-dependent
MEF-2 response also regulates genes encoding key proteins
present in the junctional sarcoplasmic reticulum membrane, a
subcellular compartment that makes up the calcium release
site of striated muscle cells and that is crucial for delivery of
calcium signal to the cell. It is tempting to speculate that the
modulation of the expression of junctin may affect the calcium
fluxes via the quaternary complex containing the calcium re-
lease channel RYR. This in turn may influence activation and
inhibition of cellular response to calcium signal, including the
coordination of the transcription of genes encoding these pro-
teins. The definition of the transcription factor(s) involved in
regulation of genes responsible of calcium signaling will be
important for elucidation of the correlation between excita-
tion-contraction and excitation-transcription coupling, two in-
timately related but functionally distinct mechanisms which are
crucial to the functional and structural integrity of striated
muscle.
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